vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $13.3M, roughly 1.6× Laird Superfood, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -13.2%, a 20.4% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 15.0%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 16.1%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
CUE vs LSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $13.3M |
| Net Profit | $1.6M | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | 9.0% | -13.5% |
| Net Margin | 7.2% | -13.2% |
| Revenue YoY | 1292.3% | 15.0% |
| Net Profit YoY | 116.7% | -341.4% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $13.3M | ||
| Q3 25 | $2.1M | $12.9M | ||
| Q2 25 | $3.0M | $12.0M | ||
| Q1 25 | $421.0K | $11.7M | ||
| Q4 24 | $1.6M | $11.6M | ||
| Q3 24 | $3.3M | $11.8M | ||
| Q2 24 | $2.7M | $10.0M | ||
| Q1 24 | $1.7M | $9.9M |
| Q4 25 | $1.6M | $-1.8M | ||
| Q3 25 | $-7.4M | $-975.1K | ||
| Q2 25 | $-8.5M | $-362.2K | ||
| Q1 25 | $-12.3M | $-156.2K | ||
| Q4 24 | — | $-398.4K | ||
| Q3 24 | $-8.7M | $-166.1K | ||
| Q2 24 | $-10.2M | $-239.1K | ||
| Q1 24 | $-12.3M | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | 9.0% | -13.5% | ||
| Q3 25 | -353.4% | -7.7% | ||
| Q2 25 | -292.3% | -3.3% | ||
| Q1 25 | -2921.4% | -1.9% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | -264.2% | -2.3% | ||
| Q2 24 | -390.6% | -3.4% | ||
| Q1 24 | -737.8% | -11.0% |
| Q4 25 | 7.2% | -13.2% | ||
| Q3 25 | -346.6% | -7.6% | ||
| Q2 25 | -287.1% | -3.0% | ||
| Q1 25 | -2911.4% | -1.3% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | -259.6% | -1.4% | ||
| Q2 24 | -382.7% | -2.4% | ||
| Q1 24 | -719.1% | -10.3% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.20 | — | ||
| Q1 24 | $-0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $11.5M |
| Total Assets | $42.2M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $5.1M | ||
| Q3 25 | $11.7M | $5.1M | ||
| Q2 25 | $27.5M | $3.9M | ||
| Q1 25 | $13.1M | $7.0M | ||
| Q4 24 | $22.5M | $8.3M | ||
| Q3 24 | $32.4M | $7.9M | ||
| Q2 24 | $30.0M | $7.6M | ||
| Q1 24 | $41.0M | $7.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $11.5M | ||
| Q3 25 | $13.2M | $12.8M | ||
| Q2 25 | $18.2M | $13.4M | ||
| Q1 25 | $6.6M | $13.3M | ||
| Q4 24 | $17.5M | $13.2M | ||
| Q3 24 | $25.4M | $13.1M | ||
| Q2 24 | $21.6M | $12.6M | ||
| Q1 24 | $30.0M | $12.7M |
| Q4 25 | $42.2M | $19.2M | ||
| Q3 25 | $31.6M | $18.9M | ||
| Q2 25 | $40.7M | $20.4M | ||
| Q1 25 | $22.3M | $21.5M | ||
| Q4 24 | $32.2M | $19.3M | ||
| Q3 24 | $44.8M | $18.8M | ||
| Q2 24 | $42.3M | $18.0M | ||
| Q1 24 | $54.0M | $17.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $68.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $68.4K | ||
| Q3 25 | $-9.0M | $1.2M | ||
| Q2 25 | $-3.4M | $-2.8M | ||
| Q1 25 | $-8.2M | $-1.3M | ||
| Q4 24 | $-36.3M | $339.2K | ||
| Q3 24 | $-7.5M | $305.8K | ||
| Q2 24 | $-10.0M | $642.7K | ||
| Q1 24 | $-9.8M | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-9.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | — | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | — | ||
| Q2 24 | -376.2% | — | ||
| Q1 24 | -573.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
